Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
UBS analyst Kevin Caliendo maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the price target from $180 to $190.
Mizuho analyst Ann Hynes maintains Quest Diagnostics (NYSE:DGX) with a Outperform and raises the price target from $190 to $...
Evercore ISI Group analyst Elizabeth Anderson maintains Quest Diagnostics (NYSE:DGX) with a In-Line and raises the price tar...
Collaboration to enable streamlined and accelerated access to Shield blood-based colorectal cancer screening test across Quest&...
With the most comprehensive Epic integration by a laboratory provider, collaboration will streamline and strengthen the custome...
New Service Empowers Clinicians with Personalized Insights from Coriell Life Sciences to Optimize Prescribing Across Specialtie...
Parties to build state-of-the-art laboratory in Southfield to serve physicians and patients across the stateQuest will also man...
